Transparency Report — Inaugural Edition

• Total intakes received in the period.
• Percentage of intakes for which a prescription was issued.
• Percentage of intakes declined for clinical reasons.
• Percentage of intakes declined for eligibility reasons, including state, age, and identity verification.
• Percentage of intakes withdrawn by the patient before review.
• Median and 90th-percentile time from intake submission to clinician decision.

• Distribution of medications prescribed, including compounded semaglutide, compounded tirzepatide, and other medications.
• Distribution of starting doses.
• Median duration of patients on therapy at the close of the period.
• Reasons for discontinuation in aggregate categories such as side effects, insufficient response, achieved goal, cost, lifestyle, lost to follow-up, and clinically discontinued.

• State-level distribution of patients, including counts and percentages.
• Number of states in which Teledris Health is currently operating.

• Age distribution.
• Sex / gender distribution as collected.
• Language preference distribution, including English and Spanish.

• Aggregate number of adverse events reported through patient-initiated channels, by severity category.
• Number of FDA Adverse Event Reporting System submissions made by Teledris Health partners on behalf of patients during the period, as available.
• Number of internal Serious Adverse Event reviews opened and closed.

• Total grievances received, by category.
• Median time to acknowledgment.
• Median time to written response.
• Aggregate resolution outcomes.
• Net satisfaction score from post-care surveys, if collected.

• Number of subpoenas, court orders, search warrants, or other lawful process received seeking patient information.
• Number complied with.
• Number challenged or narrowed.
• Categories of requesting authorities, including federal, state, local, criminal, civil, and regulatory.

• Number of HIPAA reportable breaches affecting Teledris Health patients in the period.
• Number of non-reportable security incidents reviewed.
• Status of annual HIPAA risk assessment and SOC 2 attestation, when applicable.

• Number of CCPA requests received by category.
• Number granted, partially granted, or denied.
• Median response time.
• Number of HIPAA access, amendment, accounting, and restriction requests received and processed.

• Number of licensed clinicians actively providing care.
• States covered.
• Median clinician panel size.
• Whether clinicians are W-2 employees of the Affiliated Provider, contractors, or both.

Teledris Health, operated by KavrenTech, is the management services entity. Clinical care is delivered by [Affiliated Professional Entity Name], a professional medical entity whose clinicians are licensed in the states we serve.

The compounding pharmacies dispensing medication to Teledris Health patients are [Pharmacy Partner List — to be confirmed]. Each is licensed in the relevant states and follows USP <797> sterile compounding standards.

Patient-facing and clinical infrastructure partners include our electronic health record, secure messaging, telephony, identity verification, payment processing, and analytics providers.

We commit to engaging an independent auditor for SOC 2 Type II attestation no later than 24 months after launch. We do not currently have a formal patient advisory board and are evaluating one for year two.